Neoadjuvant Chemotherapy Therapy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 25, 2024 Category: Allergy & Immunology Authors: Xuhua HuangLinhai ZhuWeifeng PanJian Hua Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Chinab Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine Source Type: research

An Unusual Cause of Insidious Back and Shoulder Pain in a Man: A Case Report
In this study, we aimed to raise awareness by presenting the first reported isolated hydatid cyst in the infraspinatus muscle case from our country, which is extremely rare.PMID:38654945 | PMC:PMC11033544 | DOI:10.18502/ijpa.v19i1.15220 (Source: Iranian Journal of Parasitology)
Source: Iranian Journal of Parasitology - April 24, 2024 Category: Parasitology Authors: O ğuz Kaya Nevzat G önder Source Type: research

Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis
CONCLUSIONS: In this real-world analysis of patients with TNBC treated with NAC plus pembro, younger age and the completion of at least 8 cycles of pembrolizumab were associated with pCR.PMID:38656345 | DOI:10.1093/oncolo/oyae064 (Source: The Oncologist)
Source: The Oncologist - April 24, 2024 Category: Cancer & Oncology Authors: Alexis LeVee Megan Wong Sarah Flores Nora Ruel Heather McArthur James Waisman Joanne Mortimer Source Type: research

GSE241908 Transcriptomic profiles of ovarian cancer cells isolated from paired cancer ascites before and after chemotherapy
Contributors : Ksenia S Anufrieva ; Victoria O ShenderSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensChemotherapy in complex with surgical removal remain the most common approaches in cancer treatment, but their effectiveness is limited by the emergence of chemoresistance. In order to reveal changes in transcriptomic profiles of cancer cells remaining after platinum-based chemotherapy, we created primary cultures of cancer cells isolated from paired ascites of ovarian cancer patients taken at the time of diagnosis and after neoadjuvant chemotherapy. Enrichment analysis revealed signi...
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
ConclusionsIn our cohort, HER2-low TNBC patients exhibits specific clinical characteristics and response features to NAC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 24, 2024 Category: Cancer & Oncology Source Type: research

Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer
CONCLUSIONS: Pretreatment microRNA profiles could be used to select subgroups of patients who benefited more from primary debulking surgery or neoadjuvant chemotherapy and might contribute to selecting the optimal primary treatment modality in advanced high-grade serous ovarian cancer patients.PMID:38651188 | DOI:10.1093/jjco/hyae051 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Takashi Uehara Juntaro Matsuzaki Hiroshi Yoshida Yuto Ogawa Junichiro Miura Hitoshi Fujimiya Yusuke Yamamoto Junpei Kawauchi Satoko Takizawa Kan Yonemori Hiromi Sakamoto Ken Kato Mitsuya Ishikawa Takahiro Ochiya Source Type: research

Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer
CONCLUSIONS: Pretreatment microRNA profiles could be used to select subgroups of patients who benefited more from primary debulking surgery or neoadjuvant chemotherapy and might contribute to selecting the optimal primary treatment modality in advanced high-grade serous ovarian cancer patients.PMID:38651188 | DOI:10.1093/jjco/hyae051 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Takashi Uehara Juntaro Matsuzaki Hiroshi Yoshida Yuto Ogawa Junichiro Miura Hitoshi Fujimiya Yusuke Yamamoto Junpei Kawauchi Satoko Takizawa Kan Yonemori Hiromi Sakamoto Ken Kato Mitsuya Ishikawa Takahiro Ochiya Source Type: research

Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey
CONCLUSION: In the context of early-stage HER2+ breast cancer in Spain, a notable diversity in therapeutic approaches was observed. The majority of interviewed medical oncologists acknowledged HER2DX as a clinically valuable test for specific patients, in line with the 2022 SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer. To facilitate the full integration of HER2DX into clinical guidelines, conducting prospective studies to further validate its efficacy and utility was recommended.PMID:38653928 | DOI:10.1007/s12094-024-03409-4 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Olga Mart ínez-Sáez Javier Cort és Eva Ciruelos Mercedes Mar ín-Aguilera Gloria Gonz ález Laia Par é Adriana Herrera Patricia Villagrasa-Gonz ález Aleix Prat Miguel Mart ín Source Type: research

Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis
Lung cancer is the second most commonly diagnosed cancer and was the leading cause of cancer death in 2023 [1]. Non-small cell lung cancer (NSCLC) is the most common histopathological type, constituting almost 85  % of all lung cancer cases [2]. Only 20–25 % of patients are eligible for surgery, and surgical resection remains the mainstay treatment for resectable NSCLC [3]. Despite undergoing surgery, patients remain at high risk for recurrence and death after surgery. Neoadjuvant chemotherapy or adjuv ant chemotherapy improves the 5-year survival rate by only about 5 % [4]. (Source: Lung Cancer)
Source: Lung Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Shu-Ling Zhang, Yuan Tian, Jing Yu, Jie-Hui Zhang, Li Sun, Le-Tian Huang, Jie-Tao Ma, Cheng-Bo Han Source Type: research

Cancers, Vol. 16, Pages 1623: Axillary Surgery for Breast Cancer in 2024
ber Axillary surgery for patients with breast cancer (BC) in 2024 is becoming increasingly specific, moving away from the previous &lsquo;one size fits all&rsquo; radical approach. The goal is to spare morbidity whilst maintaining oncologic safety. In the upfront surgery setting, a first landmark randomized controlled trial (RCT) on the omission of any surgical axillary staging in patients with unremarkable clinical examination and axillary ultrasound showed non-inferiority to sentinel lymph node (SLN) biopsy (SLNB). The study population consisted of 87.8% postmenopausal patients with estrogen receptor-...
Source: Cancers - April 23, 2024 Category: Cancer & Oncology Authors: Martin Heidinger Walter P. Weber Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1619: Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC
theadou Non-small cell lung cancer, even when diagnosed in early stages, has been linked with poor survival rates and distant recurrence patterns. Novel therapeutic approaches harnessing the immune system have been implemented in early stages, following the designated steps of advanced NSCLC treatment strategies. Immune-checkpoint inhibitor (ICI) regimens as monotherapy, combinational, or alongside chemotherapy have been intensely investigated as adjuvant, neoadjuvant, and, more recently, perioperative therapeutic strategies, representing pivotal milestones in the evolution of early lung cancer management while holding...
Source: Cancers - April 23, 2024 Category: Cancer & Oncology Authors: Evangelia Bogatsa George Lazaridis Chrysoula Stivanaki Eleni Timotheadou Tags: Review Source Type: research

Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma
ConclusionNeoadjuvant chemoimmunotherapy of HNSCC showed high rate of pathological response and low recurrence rate, holding promise for becoming the new standard of care for resectable HNSCC. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Imaging in the era of risk-adapted treatment in Colon cancer
Br J Radiol. 2024 Apr 22:tqae061. doi: 10.1093/bjr/tqae061. Online ahead of print.ABSTRACTThe treatment landscape for patients with colon cancer is continuously evolving. Risk-adapted treatment strategies, including neoadjuvant chemotherapy and immunotherapy, are slowly finding their way into clinical practice and guidelines. Radiologists are pivotal in guiding clinicians toward the most optimal treatment for each colon cancer patient. This review provides an overview of recent and upcoming advances in the diagnostic management of colon cancer and the radiologist's role in the multidisciplinary approach to treating colon c...
Source: The British Journal of Radiology - April 22, 2024 Category: Radiology Authors: Max J Lahaye Doenja M J Lambregts Arend G J Aalbers Petur Snaebjornsson R G H Beets-Tan Niels F M Kok Source Type: research

Molecules, Vol. 29, Pages 1896: Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma
Tester Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide. While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC patients present with locally advanced disease which is associated with a 10&ndash;15% 5-year survival rate and poor overall prognosis. Muscle-invasive bladder cancer (MIBC) is associated with about 50% 5 year survival when treated by radical cystectomy or trimodality therapy; stage IV disease is associated with 10&ndash;15% 5 year survival. Current therapeutic modalities for MIBC include neoadjuvant chemotherapy, surgery and...
Source: Molecules - April 22, 2024 Category: Chemistry Authors: Aditya Eturi Amman Bhasin Kevin K. Zarrabi William J. Tester Tags: Review Source Type: research